Schedule 8 medicines are subject to strict legislative controls due to their high potential for misuse, abuse and dependence.
The most commonly used Schedule 8 medicines include analgesics such as opioids (for example, morphine, fentanyl, oxycodone, tapentadol, hydromorphone, methadone and buprenorphine). The benzodiazepines flunitrazepam and alprazolam are also included in Schedule 8 due to evidence of illicit use and risk of dependence.
Note: Schedule 8 medicines are also known as drugs of addiction, drugs of dependence, or controlled drugs.
The following table lists examples of Schedule 8 medicines. For an exhaustive list of Schedule 8 medicines refer to
The Poisons Standard (SUSMP).
alfentanil | Rapifen® |
---|
alprazolam | Kalma®, Alprax® |
---|
amobarbital1 (amylobarbitone) | Amytal® |
---|
amfetamine (amphetamine) | |
---|
buprenorphine | Norspan®, Suboxone®, Temgesic® |
---|
butorphanol | Torbugesic®, Dolorex®, Butorgesic® |
---|
cannabis2 | |
---|
cocaine | |
---|
codeine3 | Codeine Linctus®, Codeine Phos Tablets® |
---|
dexamfetamine (dexamphetamine) | |
---|
dextropropoxyphene4 | |
---|
dihydrocodeine5 | |
---|
diphenoxylate6 | |
---|
dronabinol7 | |
---|
fentanyl | Actiq®, Denpax®, Durogesic®, Fenpatch® |
---|
flunitrazepam | Hypnodorm® |
---|
hydromorphone | Dilaudid®, Jurnista® |
---|
ketamine | Ketalar®, Ketamil®, Ketavet®, Ketamav® |
---|
(N, α dimethyl 3,4 (methylenedioxy)phenylethylamine)8 | |
---|
lisdexamfetamine | Vyvanse® |
---|
methadone | Biodone Forte®, Physeptone®, Methadone® |
---|
methylamfetamine (methylamphetamine) | |
---|
methylphenidate | Concerta®, Ritalin® |
---|
morphine | Kapanol®, MS Contin®, Ordine® |
---|
nabilone | |
---|
nabiximols9 | Sativex® |
---|
opium10 | |
---|
oxycodone | Endone®, Oxycontin®, Oxynorm®, Targin® |
---|
pentobarbital11 (pentobarbitone) | |
---|
pethidine | |
---|
pholcodine12 | |
---|
psilocybine13 | |
---|
quinalbarbitone (secobarbital) | |
---|
remifentanil | Ultiva® |
---|
secobarbital (secobarbitone,quinalbarbitone) | |
---|
sodium oxybate14 | |
---|
tapentadol | Palexia® |
---|
tetrahydrocannabinols15 | |
---|
-
except when included in schedule 4
-
(including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:
- cultivated or produced, or in products manufactured, in accordance with the narcotic drugs act 1967; and/or
- for use in products manufactured in accordance with the narcotic drugs act 1967; and/or
- imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
- in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
except when:
- it is a product to which item 4, 8, 10, 11 or 12 of schedule 5a to the therapeutic goods regulations 1990 applies; or
- separately specified in schedule 4; or
- separately specified in the nabiximols entry in this schedule; or
- in hemp seed oil for purposes other than internal human therapeutic use containing 50 mg/kg or less of cannabinoids
-
except when included in schedule 2, 3 or 4
-
except when included in schedule 4
-
except when included in schedule 2, 3 or 4
-
except when included in schedule 3 or 4
-
(delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use
-
in preparations for human therapeutic use for the treatment of post-traumatic stress disorder when:
- prescribed, or its supply is authorised, by a medical practitioner:
- registered as a specialist psychiatrist under the Health Practitioner Regulation National Law;
- for whom an authority under the TGA Authorised Prescriber Scheme that covers MDMA is in force
-
(botanical extract of cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use
- except the alkaloids noscapine in schedule 2 and papaverine when included in schedule 2 or 4
-
except when included in schedule 4
-
except when included in schedule 2 or 4
in preparations for human therapeutic use for the treatment of treatment-resistant depression, when:
- prescribed, or its supply is authorised, by a medical practitioner:
- registered as a specialist psychiatrist under the Health Practitioner Regulation National Law; and
- for whom an authority under the TGA Authorised Prescriber Scheme that covers psilocybine is in force
- for human therapeutic use
-
when extracted from cannabis for human therapeutic use, when:
- included in products manufactured in accordance with the narcotic drugs act 1967; and/or
- imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the therapeutic goods act 1989; and/or
- in therapeutic goods supplied in accordance with the therapeutic goods act 1989,
except when:
- it is in a product to which item 4, 8, 10, 11 or 12 of schedule 5a to the therapeutic goods regulations 1990 applies; or
- in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with either of the following warning statements:
- not for internal use; or
- not to be taken; or
- in products for purposes other than for internal human use containing 50 mg/kg or less of tetrahydrocannabinols or
- separately specified in the nabiximols entry in this schedule
For further information, please contact Pharmaceutical Services using our Online Enquiry Form.